Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for BICALUTAMIDE
- Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer
- Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer
- Bicalutamide Therapy in Young Women With NAFLD and PCOS
- Contributions to Hypertension With Androgen Deprivation Therapy
- The RolE oF Androgen Excess in MUscle Energy MetaboLism in Women With PolyCystic Ovary Syndrome (REFUEL PCOS) Study 2
- Phase II Dutasteride in Combination With CAB vs CAB in SDC
- A Phase II Randomized Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
- Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
- Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
- Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
- SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy
- Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit
- Proxalutamide Treatment for COVID-19 Female Outpatients
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
- Camostat With Bicalutamide for COVID-19
- Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
- Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection
- Anti-Androgen Treatment for COVID-19
- Trial to Promote Recovery From COVID-19 With Endocrine Therapy
- Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
- INTREPId (INTermediate Risk Erection PreservatIon Trial)
- A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.
- Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
- Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
- A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
- Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
- Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
- Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
- Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14
- Ribociclib and Bicalutamide in AR+ TNBC
- Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
- Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer
- A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
- Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
- Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer
- Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer
- Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)
- A Study of Definitive Therapy to Treat Prostate Cancer
- FDHT PET and Bicalutamide in Metastatic Breast Cancer
- A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients
- Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer
- Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients
- Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)
- Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer
- Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
- An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
- Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer
- Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy
- Micro RNAs to Predict Response to Androgen Deprivation Therapy
- AR-inhibitor Bicalutamide in Treating Patients With TNBC
- Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients
- Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.
- High-Dose Brachytherapy in Treating Patients With Prostate Cancer
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
- Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
- A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance
- A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
- Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate
- A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
- LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
- Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
- Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
- Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
- S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
- Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
- Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy
- Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
- Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
- TAK-700 in Castration Resistant Prostate Cancer
- Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
- Oral Mucosal Absorption Study of Bicalutamide New Formulation
- Bioequivalence of Bicalutamide New Formulation in Japan
- Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
- A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
- Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
- Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
- Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
- Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
- Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
- Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet in Healthy Subjects Under Fed Conditions
- Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex 50 mg Tablet in Healthy Subjects Under Fasting Conditions
- Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer
- Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
- Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fasting Conditions
- Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fed Conditions
- Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions
- Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions
- Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
- Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer
- Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
- Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
- Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
- Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
- Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy
- Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
- Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
- Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
- Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
- Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer
- Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)
- Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
- Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
- Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
- Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.
- CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer
- Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer
- Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy
- (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
- Casodex vs Placebo in Non-Metastatic Early Prostate Cancer
- R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
- Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer
- Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
- Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer
- Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
- Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer
- Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer
- RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
- Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer
- Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
- Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Ca
- Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients.
- Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer
- Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
- Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS)
- Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
- Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
- Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
- A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)
- Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
- Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
- Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
- Intensity-Modulated Radiation Therapy, Docetaxel, and Hormone Therapy in Treating Patients With High-Risk Locally Advanced Prostate Cancer With Pelvic Lymph Node Metastasis
- Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
- Bicalutamide in Treating Patients With Metastatic Breast Cancer
- Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
- A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer
- Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide
- Survival Outcomes and Tumor Molecular Profile Following Bicalutamide Neoadjuvant Therapy
- External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
- Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
- Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
- Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer
- Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
- Casodex/Zoladex Biomarkers in Localised Prostate Cancer
- Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
- CMAB vs IMAB in Metastatic Prostate Cancer
- Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer
- Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
- Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
- Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy
- A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
- Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
- Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
- Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]
- Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy
- Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
- Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
- Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer
- Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
- S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
- SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
- Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
- Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
- Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer
- Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum
- Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
- Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
- S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
- Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
- Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
- Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
- Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
- Hormone Therapy in Treating Patients With Advanced Prostate Cancer
- Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
- Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
- SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
- Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
Clinical trials list
click for details